Press Releases Any 2022 2021 2020 (-) 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2019 March 12, 2020 argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology December 6, 2019 argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting November 25, 2019 argenx Announces Upcoming Investor Events November 24, 2019 argenx announces results of Extraordinary General Meeting of Shareholders November 11, 2019 argenx announces closing of global offering November 7, 2019 argenx announces full exercise of underwriters’ option to purchase additional ADSs November 6, 2019 argenx raises $484 million in gross proceeds in a global offering November 5, 2019 argenx announces launch of proposed global offering November 5, 2019 argenx to Present Data at Upcoming 61st American Society of Hematology (ASH) Annual Meeting October 29, 2019 argenx to Participate in Upcoming Investor Conferences October 23, 2019 argenx reports third quarter 2019 financial results and provides business update October 13, 2019 Invitation to the extraordinary shareholders’ meeting Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
